Purdue's Anti-Abuse OxyContin Patent Claims Found Invalid
By Brandon Lowrey (April 8, 2015, 6:26 PM EDT) -- A New York federal judge on Wednesday ruled that although Amneal Pharmaceuticals LLC infringed Purdue Pharma LP's patent with its generic version of an abuse-resistant variety of the pain medication OxyContin, Purdue's asserted claims are invalid as obvious and indefinite.
U.S. District Judge Sidney H. Stein's ruling draws on evidence introduced in two trials in the multidistrict litigation stemming from generic drugmakers' attempts to market their own versions of the enhanced iteration of the popular pain pills that use a gelling agent to deter abuse by snorting or injection. Purdue accused Amneal of infringing its U.S. Patent No. 8,337,888.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!